<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03325114</url>
  </required_header>
  <id_info>
    <org_study_id>66282</org_study_id>
    <secondary_id>1K23DK114477-01</secondary_id>
    <nct_id>NCT03325114</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Chlorthalidone in Type 1 Diabetes</brief_title>
  <official_title>Safety and Efficacy of Chlorthalidone to Reduce Urinary Calcium Excretion in Adolescents/Yount Adult With Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This open-label study will determine if chlorthalidone is safe and effective for the use of&#xD;
      reducing urinary calcium excretion over 4 weeks in subjects with type 1 diabetes&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type 1 diabetes (T1D) is associated with increased urinary calcium loss, which may contribute&#xD;
      to the low bone mineral density and increased fracture risk observed in patients with this&#xD;
      condition. Chlorthalidone is a thiazide-like diuretic that is commonly used to reduce urinary&#xD;
      calcium excretion in other conditions such as idiopathic hypercalciuria. Its safety and&#xD;
      efficacy has not been specifically tested in an adolescent type 1 diabetes population.&#xD;
&#xD;
      T1D subjects with hypercalciuria and who meet inclusion/exclusion criteria will be given&#xD;
      chlorthalidone daily. Blood and urine tests, blood pressure, and glycemic control will be&#xD;
      assessed at weekly study visits for 4 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    COVID restrictions prohibit further study activies&#xD;
  </why_stopped>
  <start_date type="Actual">June 28, 2019</start_date>
  <completion_date type="Actual">June 1, 2020</completion_date>
  <primary_completion_date type="Actual">June 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary Calcium Excretion</measure>
    <time_frame>Assessed at baseline and at 4 weeks</time_frame>
    <description>Change in 24 hour urine calcium excretion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hypokalemia</measure>
    <time_frame>Assessed weekly for up to 4 weeks or until hypokalemia develops</time_frame>
    <description>Serum potassium decreased to &lt;3.5 milliequivalent/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hypercalcemia</measure>
    <time_frame>Assessed weekly for up to 4 weeks or until hypercalcemia develops</time_frame>
    <description>Serum calcium increased to &gt;10.5 mg/dL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hyperglycemia</measure>
    <time_frame>Assessed at baseline and at 4 weeks</time_frame>
    <description>Change in serum fructosamine</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <condition>Hypercalciuria</condition>
  <arm_group>
    <arm_group_label>Chlorthalidone</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Chlorthalidone 12.5-50 mg by mouth daily for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chlorthalidone</intervention_name>
    <description>Chlorthalidone 12.5-5 mg by mouth daily for 4 weeks</description>
    <arm_group_label>Chlorthalidone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of T1D&#xD;
&#xD;
          -  Age 12-21 years&#xD;
&#xD;
          -  Tanner Stage 2 or greater pubertal development&#xD;
&#xD;
          -  Urine calcium excretion ≥ 4 mg/kg/day&#xD;
&#xD;
          -  Able to swallow pills&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  BMI &gt; 99th percentile for age (&lt;18 years) or BMI &gt;35 kg/m2 (≥ 18 years)&#xD;
&#xD;
          -  Coexistent conditions that may affect calcium metabolism including:&#xD;
&#xD;
               -  celiac disease&#xD;
&#xD;
               -  Graves' Disease&#xD;
&#xD;
               -  Addison's disease&#xD;
&#xD;
               -  hypo- or hyperparathyroidism&#xD;
&#xD;
          -  History of diabetes related complications including:&#xD;
&#xD;
               -  neuropathy&#xD;
&#xD;
               -  retinopathy&#xD;
&#xD;
               -  nephropathy&#xD;
&#xD;
               -  gastroparesis&#xD;
&#xD;
          -  History of oral or inhaled corticosteroid use for ≥ 5 consecutive days within the past&#xD;
             month&#xD;
&#xD;
          -  History of any diuretic use within the past month&#xD;
&#xD;
          -  Laboratory abnormalities on screening bloodwork including:&#xD;
&#xD;
               -  estimated glomerular filtration rate &lt;90 mL/min per 1.73 m2 of body surface area&#xD;
&#xD;
               -  serum calcium &gt;10.5 mg/dL&#xD;
&#xD;
               -  serum potassium &lt;3.5 mmol/L&#xD;
&#xD;
          -  Systolic or diastolic blood pressure &lt;5th percentile for age and sex50 for age &lt;18&#xD;
             years or systolic &lt;90 mmHg or diastolic blood pressure &lt;60 mmHG for age ≥18 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>October 20, 2017</study_first_submitted>
  <study_first_submitted_qc>October 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2017</study_first_posted>
  <results_first_submitted>December 8, 2020</results_first_submitted>
  <results_first_submitted_qc>December 8, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 5, 2021</results_first_posted>
  <last_update_submitted>December 8, 2020</last_update_submitted>
  <last_update_submitted_qc>December 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>type 1 diabetes</keyword>
  <keyword>hypercalciuria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Hypercalciuria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chlorthalidone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data will be available in aggregate. No plan to share individual data at present.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 10, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT03325114/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Chlorthalidone</title>
          <description>Chlorthalidone 12.5-50 mg by mouth daily for 4 weeks&#xD;
Chlorthalidone: Chlorthalidone 12.5-5 mg by mouth daily for 4 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Due to only one participant being enrolled there are concerns regarding patient confidentiality, therefore no data is being reported.</population>
      <group_list>
        <group group_id="B1">
          <title>Chlorthalidone</title>
          <description>Chlorthalidone 12.5-50 mg by mouth daily for 4 weeks&#xD;
Chlorthalidone: Chlorthalidone 12.5-5 mg by mouth daily for 4 weeks</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                </category>
                <category>
                  <title>Male</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                </category>
                <category>
                  <title>Asian</title>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                </category>
                <category>
                  <title>Black or African American</title>
                </category>
                <category>
                  <title>White</title>
                </category>
                <category>
                  <title>More than one race</title>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <class_list>
            <class>
              <title>United States</title>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Urinary Calcium Excretion</title>
        <description>Change in 24 hour urine calcium excretion</description>
        <time_frame>Assessed at baseline and at 4 weeks</time_frame>
        <population>Due to only one participant being enrolled there are concerns regarding patient confidentiality, therefore no data is being reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Chlorthalidone</title>
            <description>Chlorthalidone 12.5-50 mg by mouth daily for 4 weeks&#xD;
Chlorthalidone: Chlorthalidone 12.5-5 mg by mouth daily for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Urinary Calcium Excretion</title>
          <description>Change in 24 hour urine calcium excretion</description>
          <population>Due to only one participant being enrolled there are concerns regarding patient confidentiality, therefore no data is being reported.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hypokalemia</title>
        <description>Serum potassium decreased to &lt;3.5 milliequivalent/L</description>
        <time_frame>Assessed weekly for up to 4 weeks or until hypokalemia develops</time_frame>
        <population>Due to only one participant being enrolled there are concerns regarding patient confidentiality, therefore no data is being reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Chlorthalidone</title>
            <description>Chlorthalidone 12.5-50 mg by mouth daily for 4 weeks&#xD;
Chlorthalidone: Chlorthalidone 12.5-5 mg by mouth daily for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Hypokalemia</title>
          <description>Serum potassium decreased to &lt;3.5 milliequivalent/L</description>
          <population>Due to only one participant being enrolled there are concerns regarding patient confidentiality, therefore no data is being reported.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hypercalcemia</title>
        <description>Serum calcium increased to &gt;10.5 mg/dL</description>
        <time_frame>Assessed weekly for up to 4 weeks or until hypercalcemia develops</time_frame>
        <population>Due to only one participant being enrolled there are concerns regarding patient confidentiality, therefore no data is being reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Chlorthalidone</title>
            <description>Chlorthalidone 12.5-50 mg by mouth daily for 4 weeks&#xD;
Chlorthalidone: Chlorthalidone 12.5-5 mg by mouth daily for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Hypercalcemia</title>
          <description>Serum calcium increased to &gt;10.5 mg/dL</description>
          <population>Due to only one participant being enrolled there are concerns regarding patient confidentiality, therefore no data is being reported.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hyperglycemia</title>
        <description>Change in serum fructosamine</description>
        <time_frame>Assessed at baseline and at 4 weeks</time_frame>
        <population>Due to only one participant being enrolled there are concerns regarding patient confidentiality, therefore no data is being reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Chlorthalidone</title>
            <description>Chlorthalidone 12.5-50 mg by mouth daily for 4 weeks&#xD;
Chlorthalidone: Chlorthalidone 12.5-5 mg by mouth daily for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Hyperglycemia</title>
          <description>Change in serum fructosamine</description>
          <population>Due to only one participant being enrolled there are concerns regarding patient confidentiality, therefore no data is being reported.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 weeks</time_frame>
      <desc>Due to only one participant being enrolled there are concerns regarding patient confidentiality, therefore no data is being reported.</desc>
      <group_list>
        <group group_id="E1">
          <title>Chlorthalidone</title>
          <description>Chlorthalidone 12.5-50 mg by mouth daily for 4 weeks&#xD;
Chlorthalidone: Chlorthalidone 12.5-5 mg by mouth daily for 4 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Carrie Dykes</name_or_title>
      <organization>University of Rochester</organization>
      <phone>15852750736</phone>
      <email>carrie_dykes@urmc.rochester.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

